No Data
No Data
Cellectar Biosciences Enhances CEO and COO Severance Benefits
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Hold Rating
Cellectar Biosciences: Promising Future With FDA Clarity and Innovative Radiopharmaceutical Advancements
Oppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)
Earnings Call Summary | Cellectar BioSciences(CLRB.US) Q4 2024 Earnings Conference
CELLECTAR BIOSCIENCES Earnings Results: $CLRB Reports Quarterly Earnings
70828616 : What do you mean